Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Urological cancer

Enzalutamide in metastatic CRPC—old dog, new tricks

Nature Reviews Clinical Oncology volume 9, pages 613–614 (2012)Cite this article

Subjects

Two novel agents targeting the androgen receptor signalling axis, even after chemotherapy treatment, have been demonstrated to be effective in patients with metastatic castration-resistant prostate cancer (CRPC). Enzalutamide is the newest approved treatment that improves survival in this lethal and morbid disease.

Key Points

  • Enzalutamide, a selective competitive androgen receptor antagonist with multiple inhibitory effects on the androgen signalling axis, has been approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer after chemotherapy treatment by demonstrating significant clinical activity in a randomized phase III study

  • Androgen signalling remains an important driver of prostate cancer, even in the castration-resistant setting; a pipeline of novel treatments further targeting this pathway has entered various stages of development and clinical testing

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).

    PubMed  Google Scholar 

  2. Ryan, C. J., Elkin, E. P., Small, E. J., Duchane, J. & Carroll, P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol. Oncol. 24, 396–402 (2006).

    Article  PubMed  Google Scholar 

  3. Huggins, C., Stephens, R. C. & Hodges, C. V. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209–223 (1941).

    Article  CAS  Google Scholar 

  4. Tsao, C. K., Small, A. C., Galsky, M. D. & Oh, W. K. Overcoming castration resistance in prostate cancer. Curr. Opin. Urol. 22, 167–174 (2012).

    Article  PubMed  Google Scholar 

  5. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375, 1437–1446 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov[online], (2012).

  10. Buchman, A. L. Side effects of corticosteroid therapy. J. Clin. Gastroenterol. 33, 289–294 (2001).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, The Tisch Cancer Institute, 1 Gustave L. Levy Place, New York, 10029, NY, USA

    Che-Kai Tsao & William K. Oh

Authors
  1. Che-Kai Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William K. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William K. Oh.

Ethics declarations

Competing interests

W. K. Oh has acted as a consultant for the following companies: Astellas Pharma, Janssen and Medivation. C.-K. Tsao declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsao, CK., Oh, W. Enzalutamide in metastatic CRPC—old dog, new tricks. Nat Rev Clin Oncol 9, 613–614 (2012). https://doi.org/10.1038/nrclinonc.2012.181

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.181

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing